Why BioSante Expects a Positive Review of Drug for Female Sexual Disorder

By Len Zehr: BioSante Pharmaceuticals’ (BPAX) successful pharmacokinetic study of its LibiGel (testosterone gel) treatment for female sexual dysfunction, specifically hypoactive sexual desire disorder (HSDD), is adding to the company’s overall confidence that its ongoing, long-term safety study also will be favorable, as will its efficacy trials.

By Ganaxi Small Cap Movers:Biosante Pharmaceuticals (BPAX) announced after the market closed today that its lead product in development, Libigel, often incorrectly called Viagra for women, had failed based on an initial analysis of data from two pivotal phase 3 efficac

By M.E. Garza: BioSante Pharmaceuticals, Inc. (BPAX) has just shared some additional data from its principal LibiGel (testosterone gel) pharmacokinetic (pK) study. Will that be enough to break shares away from down-trending resistance levels?

Zacks.com submits: Recently, VIVUS Inc. (VVUS) announced encouraging phase II results from a study conducted with Qnexa for the treatment of patients suffering from obstructive sleep apnea ((OSA)).

By James Stocklasar Thomas Jr.:Biosante (BPAX) deserves attention from the Seeking Alpha community, especially since it was at center stage of the penny-land biotech community going into December 2011. The question on Biosante's investors' minds is: Will Libigel make a comeback? I imagine answers range from the pejorative to unbridled optimism, from, 'No way!' to 'Yes way!'

Sheff Station submits:Biosante’s potential breakthrough product, Libigel, is in Phase III clinical trials for the treatment of female sexual dysfunction. Libigel does not have a partner for the product, and currently there is no pharmaceutical product approved in the U.S.

The Burrill Report submits: Antisoma (ATSMY.PK) discontinued a late-stage trial of its experimental drug for previously untreated non-small cell lung cancer patients saying a continuation of the trial “would be futile, as there is little or no prospect of demonstrating a survival benefit with ASA404 in this setting.” The news sent shares in the company tumbling down 75 percent and was followed by the departure of the company’s COO Ursula Ney.

ByAli Yasar:The news of failed Phase III efficacy studies on Libigel (testosterone gel) being used as a treatment for female sexual dysfunction (FSD) was a surprise to many Biosante Pharmaceuticals (BPAX) investors.